Anthony J. Polverino - 01 Jan 2025 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)

Reporting relationship: Director
Issuer ticker: BCLI
Reported as of: 01 Jan 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jan 2025, 17:34:52 UTC
Prior SEC filing: 03 Feb 2022
Next SEC filing: 20 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Anthony J. Polverino

Key filing fact

Anthony J. Polverino filed Form 4 for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) on 03 Jan 2025.

Key facts

This page summarizes Anthony J. Polverino's Form 4 filing for BRAINSTORM CELL THERAPEUTICS INC. (BCLI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Jan 2025, 17:34.

Change

Previous filing in this sequence was filed on 03 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCLI transaction

Common Stock

Award

Transaction value: $0
Shares: +24,000
Change %: +1387%
Price: $0.000000
Shares after: 25,730
Date: 01 Jan 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares of restricted stock units ("RSUs") awarded under the 2014 Stock Incentive Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.

Footnote F2

Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024.